Read by QxMD icon Read

Hematology/oncology and Stem Cell Therapy

Abeer Arain
Vitamins are the organic compounds that have long been known to play a significant role in our body by functioning as hormones and antioxidants. Vitamin D, a fat-soluble vitamin, is the main regulator of calcium hemostasis in our body. At the same time, it is also known to show its potential effects on the immune system by modulating the differentiation, activation, and proliferation of T and B lymphocytes. The immunomodulatory properties of vitamin D are also known to have a crucial role in the prevention and treatment of graft-versus-host disease...
September 8, 2018: Hematology/oncology and Stem Cell Therapy
Anant Vatsayan, Hasan Hashem, Kristen Nagle, Linda Cabral, Hillard Lazarus, Jignesh Dalal
Hematopoietic stem cell transplant (HSCT) with matched sibling donor (MSD) is considered the first line of therapy for patients with severe aplastic anemia (SAA) who are <40 years of age (Young, 2013) [1]. Immunosuppressive therapy (IST) and alternative donor HSCT are other modalities of treatment (Young, 2013) [1]. Due to non-availability of a MSD for two- thirds of the SAA patients and a significant rate of failure of IST, alternative donor HSCT has been tried with encouraging results (Socié, 2013) [2]...
August 29, 2018: Hematology/oncology and Stem Cell Therapy
Dorota Jaguś, Karol Lis, Longin Niemczyk, Grzegorz W Basak
Kidney dysfunction is a common complication of hematopoietic cell transplantation (HCT) with proven negative impact on early and long-term mortality. Causes of this complication are diverse, usually overlapping, and poorly understood. Therefore, management implicates multidirectional investigations and simultaneous treatment of suspected causes. The etiology is frequently unconfirmed due to a lack of specific markers and prevalence of contraindications to renal biopsy among HCT recipients. Herein, we provide a summary of etiology and propose an algorithm for evaluation of kidney injury after HCT...
July 29, 2018: Hematology/oncology and Stem Cell Therapy
Ghulam Rehman Mohyuddin, Nicole Romanelli, Leyla Shune, Sunil Abhyankar, Siddhartha Ganguly, Joseph McGuirk, Anurag Singh
No abstract text is available yet for this article.
July 29, 2018: Hematology/oncology and Stem Cell Therapy
Moussab Damlaj, Rehab Yassin, Saeed Al-Shieban, Tabreez Pasha, Mohsen Alzahrani, Ayman Alhejazi, Ahmad Alaskar
No abstract text is available yet for this article.
July 29, 2018: Hematology/oncology and Stem Cell Therapy
Guido Lancman, Alexander Coltoff, Amir Steinberg
Thrombocytopenia is a relatively common complication following allogeneic hematopoietic stem cell transplantation and is associated with increased bleeding, transfusion requirements, chronic graft-versus-host disease, and all-cause mortality. There are currently no approved treatments outside of supportive transfusions. We report on the outcomes of five patients at our institution who received romiplostim for either primary engraftment failure or secondary failure of platelet recovery following stem cell transplantation...
July 17, 2018: Hematology/oncology and Stem Cell Therapy
Zahraa Najah Mahdi, Subh S Al-Mudallal, Bassam M Hameed
OBJECTIVE/BACKGROUND: Certain hemostatic anomalies found in patients with thalassemia suggest the existence of a chronic hypercoagulable state. Several etiologic factors may play a role in the pathogenesis of the hypercoagulable state in those patients. One of these factors is abnormal thalassemic red blood cells (RBCs), which may provide a procoagulant. To substantiate these findings, we measured the ability of RBCs from thalassemia patients to bind annexin V with increased fraction of platelets carrying the activation marker CD62P (P-selectin)...
July 17, 2018: Hematology/oncology and Stem Cell Therapy
Showkat Ahmad Bhat, Manzoor Ur Rahman Mir, Sabhiya Majid, Tehseen Hassan, Muneeb U Rehman, Sonallah Kuchy
OBJECTIVE/BACKGROUND: Posttranslational modification of proteins, including glycosylation, is known to differ between normal and tumor cells. Altered glycosyltransferase levels have been observed in tumor tissues and their role in tumor metastasis and invasion has been implicated. In this study the role of altered glycosyltransferase messenger RNA (mRNA) levels in serum of gastric cancer patients as early markers of gastric cancer was evaluated. METHODS: In this case control study the expression profile of ppGalNAc-T6, GlcNAcT-V, ST3Gal I, ST3 Gal IV, and ST6GalNAc-I in normal healthy control and gastric cancer patients was compared...
September 2018: Hematology/oncology and Stem Cell Therapy
Ifeyinwa E Obiorah, Metin Ozdemirli
Myeloid sarcoma is an extramedullary tumor that consists of myeloblasts or immature myeloid cells. The neoplasm can occur in any part of the body, including the bone, periosteum, lymph nodes, skin, and soft tissue and they may occur de novo or in association with acute myeloid leukemia, myeloproliferative neoplasms and myelodysplastic syndromes. Most cases display a myelomonocytic or pure monoblastic morphology. Tumors with megakaryoblastic differentiation are extremely uncommon and may occur in association with transformation of a myeloproliferative disorder...
September 2018: Hematology/oncology and Stem Cell Therapy
Margaret Cupit-Link, Karen L Syrjala, Shahrukh K Hashmi
OBJECTIVE/BACKGROUND: Improvements in curative treatments for many types of cancer have emerged over the past several decades, resulting in a growing population of long-term cancer survivors - of both adult and childhood cancers. Despite this incredible medical achievement, long-term survivors of cancer face a unique fear: the fear of relapse. METHODS: We conducted a review of the literature for data on fear of relapse among cancer survivors. RESULTS: The fear of cancer recurrence is present in survivors of childhood and adult cancers as well as family members and often leads to psychological sequelae...
September 2018: Hematology/oncology and Stem Cell Therapy
Can Boga, Mahmut Yeral, Ciğdem Gereklioglu, Suheyl Asma, Erkan Maytalman, Pelin Aytan, Ilknur Kozanoglu, Cagla Sariturk, Hakan Ozdogu
OBJECTIVE/BACKGROUND: Anti-T lymphocyte globulin Fresenius (rATG-F; ATG-Fresenius) and antithymocyte globulin (thymoglobulin), which are included in transplant protocols, are used to reduce the risk of chronic graft-versus-host disease (cGVHD) or suppress allograft rejection. Available clinical studies have been conducted in heterogenous patient populations and with different administration protocols including stem cell sources. Additionally, the pharmacokinetics of ATG is variable, and the clinically effective dose of rATG-F, in particular, is not exactly known...
September 2018: Hematology/oncology and Stem Cell Therapy
Sarbajit Mukherjee, Adanma Ayanambakkam, Sami Ibrahimi, Sarah Schmidt, Jennifer Holter Charkrabarty, Mohamad Khawandanah
Ibritumomab Tiuxetan (Zevalin) is an anti CD-20 murine monoclonal antibody linked to the radio-isotope 90-yttrium (90Y) by the chelator Tiuxetan. It is FDA approved for treatment of relapsed low grade or follicular B-cell Non-Hodgkin's Lymphoma (NHL) or newly diagnosed follicular NHL following an initial response to first-line chemotherapy. Patients may develop Human Anti-Murine Antibodies (HAMA), following exposure to murine antibodies. There is a concern for development of hypersensitivity reactions with Ibritumomab, especially in patients with an elevated HAMA titer...
September 2018: Hematology/oncology and Stem Cell Therapy
Sherif M Badawy, Alexis A Thompson, Robert I Liem
BACKGROUND: Hydroxyurea reduces complications and improves health-related quality of life (HRQOL) in sickle cell disease (SCD) patients, however adherence remains suboptimal. Understanding patients' views of hydroxyurea is critical to optimize adherence, particularly in adolescents and young adults (AYA). Study objectives were to assess beliefs about hydroxyurea using the Beliefs about Medicines Questionnaire (BMQ), and to examine the relationship of patients' beliefs to their hydroxyurea adherence and HRQOL...
September 2018: Hematology/oncology and Stem Cell Therapy
Larisa Broglie, Alfred Rademaker, John Galvin, Ayita Ray, William T Tse, Reggie Duerst, Jennifer Schneiderman, Morris Kletzel, Sonali Chaudhury
BACKGROUND: Acute graft versus host disease (aGVHD) affects approximately 30-60% of patients after allogeneic hematopoietic stem cell transplantation (HCT) and our ability to predict who develops this complication and their response to treatment is limited. Fecal calprotectin has recently gained popularity as an effective marker of GI inflammation in patients with Inflammatory Bowel Disease (IBD). METHODS: Fecal calprotectin and albumin were evaluated as prognostic and predictive markers of aGVHD in 60 adult and pediatric HCT patients...
September 2018: Hematology/oncology and Stem Cell Therapy
Ghulam Rehman Mohyuddin, Ashley Elizabeth Clark, John Roller, Leyla Shune, Tara Lin, Neil Dunavin, Ajoy Dias, Siddhartha Ganguly, Sunil Abhyankar, Joseph McGuirk, Anurag Singh
Surveillance scans after autologous stem cell transplant (auto-HCT) for patients with relapsed/refractory (RR) diffuse large B Cell lymphoma (DLBCL) have no proven survival benefit. We studied survival differences among patients with RR DLBCL post auto-HCT whose recurrences were detected clinically versus with routine surveillance imaging. Among the 139 patients with RR DLBCL that underwent auto-HCT from 2000 to 2014 at our institution, 37 relapsed: 21 clinical and 16 radiological. The median time to progression was 167 days for the clinical cohort and 565 days for the radiological cohort (p = 0...
September 2018: Hematology/oncology and Stem Cell Therapy
Navkirti Mittal, Ruchi Gupta, Khaliqur Rahman, Tanvi Gupta, Soniya Nityanand
No abstract text is available yet for this article.
September 2018: Hematology/oncology and Stem Cell Therapy
Shebl Said Shebl, Walid Ahmed Naguib El-Shehaby, Yasmin Shebl Said, Amira Hamed Darwish, Nabeh Helal Elfadaly, Eman Amer
BACKGROUND: The precise mechanisms of the increased incidence of hemostatic abnormalities in congenital heart disease (CHD) have not been determined. The aim of the study was to evaluate some indicators of activation of platelets and vascular endothelial cells in patients with CHD, evaluation of bleeding liability of these patients, and correlation with the clinical presentation of these patients. METHODS: This work was carried out on 20 patients with cyanotic congenital heart diseases (CCHD), 20 patients with acyanotic congenital heart diseases (ACHD), and 20 healthy children who served as the control group, aged between 1 and 10years...
September 2018: Hematology/oncology and Stem Cell Therapy
Alireza Khabazi, Mahafarin Maralani, Sasan Andalib, Ebrahim Sakhinia
Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is a periodic fever syndrome inherited in an autosomal dominant fashion. It stems from mutations in the TNFRSF1A (accession number: NM_001065) gene expressing the receptor for tumor necrosis factor α. A patient with TRAPS may present with prolonged episodes of fever attacks, abdominal pain, severe myalgia, and painful erythema on the trunk or extremities. Here, we report an 8-year-old boy with febrile attacks occurring every 1-2months and continuing for 3-4days...
September 2018: Hematology/oncology and Stem Cell Therapy
Laura Prohaska, Zahra Mahmoudjafari, Leyla Shune, Anurag Singh, Tara Lin, Sunil Abhyankar, Siddhartha Ganguly, Dennis Grauer, Joseph McGuirk, Lisa Clough
OBJECTIVE/BACKGROUND: Clostridium difficile infection (CDI) is a potential complication during hematopoietic stem cell transplantation (HSCT), and no specific recommendations exist regarding treatment of CDI in allogeneic SCT patients. Use of metronidazole and oral vancomycin has been associated with clinical failure. Fidaxomicin has previously been found noninferior to the use of oral vancomycin for the treatment of CDI, and no studies have compared the use of oral vancomycin with fidaxomicin for the treatment of CDI in allogeneic SCT...
June 18, 2018: Hematology/oncology and Stem Cell Therapy
Ahmad Alshomar, Riad El Fakih
Lymphoblastic lymphomas (LBLs) are neoplasms of precursor B and T cells; they are considered in the same spectrum as precursor B and T cell acute lymphoblastic leukemia (ALL). The World Health Organization classification classifies both LBL and ALL as one disease entity. While chromosome abnormalities are well defined with all of their therapeutic and prognostic implications in ALL, these are not well studied in LBL. Here, we describe a case of Philadelphia chromosome-positive LBL and review the available literature regarding this entity...
June 15, 2018: Hematology/oncology and Stem Cell Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"